A new model of portal vein thrombosis in rats with cirrhosis induced by partial portal vein ligation plus carbon tetrachloride and intervened with rivaroxaban
Open Access
- 13 May 2024
- journal article
- research article
- Published by Springer Nature in BMC Gastroenterology
- Vol. 24 (1) , 1-13
Abstract
Background and aims: Portal vein thrombosis (PVT) is a common complication of liver cirrhosis that can aggravate portal hypertension. However, there are features of both PVT and cirrhosis that are not recapitulated in most current animal models. In this study, we aimed to establish a stable animal model of PVT and cirrhosis, intervene with anticoagulant, and explore the related mechanism. Methods: First, 49 male SD rats received partial portal vein ligation (PPVL), and 44 survival rats were divided into 6 groups: PPVL control group; 4-week, 6 -week, 8-week, and 10-week model group; and the rivaroxaban (RIVA)-treated group. The rats were intoxicated with or without carbon tetrachloride (CCl4) for 4–10 weeks. Seven normal rats were used as the normal controls. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels and parameters for blood coagulation were all assayed with kits. Liver inflammation, collagen deposition and hydroxyproline (Hyp) levels were also measured. The extrahepatic macro-PVT was observed via portal vein HE staining, etc. The intrahepatic microthrombi was stained via fibrin immunohistochemistry. The portal blood flow velocity (PBFV) and diameter were detected via color Doppler ultrasound. Vascular endothelial injury was evaluated by von Willebrand Factor (vWF) immunofluorescence. Fibrinolytic activity was estimated by western blot analysis of fibrin and plasminogen activator inhibitor-1 (PAI-1). Results: After PPVL surgery and 10 weeks of CCl4 intoxication, a rat model that exhibited characteristics of both cirrhosis and extra and intrahepatic thrombi was established. In cirrhotic rats with PVT, the PBFV decreased, both factors of pro- and anti-coagulation decreased, but with relative hypercoagulable state, vascular endothelial injured, and fibrinolytic activity decreased. RIVA-treated rats had improved coagulation function, increased PBFV and attenuated thrombi. This effect was related to the improvements in endothelial injury and fibrinolytic activity. Conclusions: A new rat model of PVT with cirrhosis was established through partial portal vein ligation plus CCl4 intoxication, with the characteristics of macrothrombi at portal veins and microthrombi in hepatic sinusoids, as well as liver cirrhosis. Rivaroxaban could attenuate PVT in cirrhosis in the model rats. The underlying mechanisms of PVT formation in the rat model and pharmacological action of rivaroxaban are related to the regulation of portal blood flow, coagulant factors, and vascular endothelial cell function.Keywords
Funding Information
- National Natural Science Foundation of China (81603467)
- Shanghai Key Specialty of Traditional Chinese Clinical Medicine (shslczdzk01201)
- “Tree-Year Action Plan” for Development of TCM in Shanghai (16CR1026B)
This publication has 24 references indexed in Scilit:
- The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cellsHepatology, 2017
- Association between portal vein thrombosis and risk of bleeding in liver cirrhosis: A systematic review of the literatureClinics and Research in Hepatology and Gastroenterology, 2015
- Portal vein thrombosis, mortality and hepatic decompensation in patients with cirrhosis: A meta-analysisWorld Journal of Hepatology, 2015
- What we should know about portal vein thrombosis in cirrhotic patients: A changing perspectiveWorld Journal of Gastroenterology, 2012
- The Coagulopathy of Chronic Liver DiseaseNew England Journal of Medicine, 2011
- Hemostasis and thrombosis in patients with liver disease: The ups and downsJournal of Hepatology, 2010
- Thrombotic risk factors in patients with liver cirrhosis: Correlation with MELD scoring system and portal vein thrombosis developmentJournal of Hepatology, 2009
- Smads 2 and 3 Are Differentially Activated by Transforming Growth Factor-β (TGF-β) in Quiescent and Activated Hepatic Stellate CellsJournal of Biological Chemistry, 2003
- Spontaneous thrombosis in mice carrying the factor V Leiden mutation.2000
- A simple method to determine nanogram levels of 4-hydroxyproline in biological tissuesAnalytical Biochemistry, 1981